<DOC>
	<DOCNO>NCT00004255</DOCNO>
	<brief_summary>RATIONALE : Bone marrow treat remove certain white blood cell may reduce chance develop graft-versus-host disease follow bone marrow transplantation . PURPOSE : Randomized phase II/III trial compare effectiveness treat bone marrow untreated bone marrow prevent graft-versus-host disease patient acute chronic leukemia undergo bone marrow transplantation .</brief_summary>
	<brief_title>Treatment Bone Marrow Prevent Graft-Versus-Host Disease Patients With Acute Chronic Leukemia Undergoing Bone Marrow Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy process ( cell deplete ) v unprocessed ( conventional ) unrelated bone marrow transplantation reduce grade III/IV acute graft v host disease ( GVHD ) patient acute chronic leukemia myelodysplastic syndrome . - Compare safety regimens patient . - Compare disease-free survival rate 100 day 6 month patient treat regimen . - Compare time engraftment percent engraftment patient treat regimen . - Compare reduction rate grade II great acute chronic GVHD patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord degree HLA matching disease ( chronic v acute ) . Acute myelogenous leukemia patient stratify accord prior myelodysplastic syndrome ( yes v ) . Patients randomize one two bone marrow transplantation arm . All patient receive condition regimen comprise fludarabine IV day -6 , cyclophosphamide IV day -5 -4 , anti-thymocyte globulin IV day -4 -2 , total body irradiation day -3 0 . Patients also receive methylprednisolone IV every 12 hour 4 dos day -2 0 . Tacrolimus IV administer continuously day -1 continue either orally IV 6 month . Bone marrow infuse day 0 . Filgrastim ( G-CSF ) administer subcutaneously day 0 blood count recover . - Arm I : Patients receive allogeneic bone marrow process produce mononuclear cell preparation . - Arm II : Patients receive unprocessed allogeneic bone marrow . Patients follow weekly 100 day 6 month . PROJECTED ACCRUAL : A total 260 patient accrue study within 17 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Acute myelogenous leukemia ( AML ) acute lymphocytic leukemia ( ALL ) first early relapse , second remission , subsequent remission AML first complete remission one follow adverse feature : Antecedent hematologic disorder myelodysplasia AML result prior chemotherapy radiotherapy More 1 course induction chemotherapy achieve remission adverse cytogenetics Philadelphia chromosome 9:22 , +8 , +11 ; abnormal 12p ; deletion chromosomes 5 , 7 , 20 ( 3:3 ) ALL first complete remission poor risk cytogenetics Philadelphia chromosome 9:22 , 8:14 , 4:11 OR WBC great 100,000/mm3 OR Time achieve complete remission 4 week Chronic myelogenous leukemia chronic accelerate phase Myelodysplastic syndrome Refractory anemia excess blast ( RAEB ) OR RAEB transformation Unrelated bone marrow donor available If match 6 6 HLAA , B , DR locus , patient must 12 50 year If match 5 6 locus , patient must 12 35 year No match sibling donor available No uncontrolled CNS leukemia PATIENT CHARACTERISTICS : Age : See Disease Characteristics 12 50 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : LVEF great 50 % without medication Pulmonary : DLCO FVC least 50 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious medical illness No uncontrolled diabetes mellitus No uncontrolled and/or active infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior immunotherapy recover At least 1 year since prior autologous transplantation No prior allogeneic transplantation Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( except hydroxyurea ) recover Endocrine therapy : At least 3 week since prior hormonal therapy recover Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover No prior radiotherapy dos would preclude study Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>